Impact of certain proteolytic agents on the development of different types of cataract.
Krasnov
M M
MM
All-Union Research Institute for Eye Disease, USSR Ministry of Health, Moscow.
Polunin
G S
GS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002386:Cataract / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002917:Chymopapain / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003720:Densitometry; D048909:Diabetes Complications; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008875:Middle Aged; D010206:Papain / Q000627:therapeutic use*; D010447:Peptide Hydrolases / Q000627:therapeutic use; D013997:Time Factors
D004338:Drug Combinations; C021701:lekozim; D010447:Peptide Hydrolases; D010206:Papain; D002917:Chymopapain